We also describe how the capacity of silibinin to attenuate a hyperactive TGFβ/SMAD signaling axis can overcome EMT-driven resistance to multiple-generation ALK–TKIs in ALK-rearranged NSCLC cells. This evidence concerns the gene ALK and non-small cell lung carcinoma.